RNAC NASDAQ
Cartesian Therapeutics, Inc.
1W: -0.7%
1M: -18.9%
3M: -28.8%
YTD: +8.9%
1Y: -28.1%
3Y: -78.5%
5Y: -94.3%
$7.36
+0.14 (+1.94%)
Weekly Expected Move ±4.3%
$7
$7
$7
$8
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (30)
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Cartesian Therapeutics Announces New Employment Inducement Grants
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $32.60
New Strong Sell Stocks for July 1st
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
12 Health Care Stocks Moving In Friday's Intraday Session
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics GAAP EPS of -$1.46 misses by $0.58
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $34.00
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics (NASDAQ:RNAC) Trading 10.3% Higher – Time to Buy?
Analysts Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $34.00
Insights into Cartesian Therapeutics Q4 Earnings
Cartesian Therapeutics GAAP EPS of -$5.02 misses by $2.67, revenue of $2.79M beats by $0.82M
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Average Price Target from Brokerages
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Average PT from Brokerages
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Consensus Target Price from Brokerages
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
Cartesian Therapeutics Announces New Employment Inducement Grants
Contrasting Beyond Air (NASDAQ:XAIR) & Cartesian Therapeutics (NASDAQ:RNAC)
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors